21st Century Approach to Treating Basal Cell Carcinoma
Hematology-Oncology
Curriculum:
A 21st Century Approach to Treating Basal Cell Carcinoma
A 21st Century Approach to Treating Basal Cell Carcinoma
Credits:
1 AMA PRA Category 1 Credit(s) ™
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
December 30, 2013
December 30, 2013
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Dermatologic Oncologists, Dermatologists
Relevant Terms:
Basal Cell Carcinoma, Dermatology
Ragini Kudchadkar, MD
Ragini Kudchadkar, MD
Medical Oncologist
Department of Cutaneous Oncology
Moffitt Cancer Center
Assistant Professor
University of South Florida College of Medicine's Department of Oncologic Sciences
Tampa, Florida
Bio
Dr. Ragini Kudchadkar is an Assistant Member at Moffitt Cancer Center and is an Assistant Professor at University of South Florida Department of Oncologic Sciences. She completed her medical school and internal medicine training at Emory University in Atlanta, Georgia and subsequently trained in Hematology/Oncology at the University of Colorado prior to joining the Moffitt faculty. Dr. Kudchadkar's primary interest is in clinical research investigating signal transduction inhibitors in melanoma as well as a secondary interest in rare cutaneous malignancies such basal cell carcinomas.
Karl Lewis, MD
Karl Lewis, MD
Assistant Professor of Medicine
Division of Medical Oncology
Associate Director
Melanoma Research Clinics
University of Colorado Denver
Denver, Colorado
Bio
Karl D. Lewis, MD, graduated from Albany Medical College and completed his residency in internal medicine at the University of California, Irvine. From there he spent two years as a fellow in hematology/oncology at the University of Colorado Health Sciences Center. Dr. Lewis is Associate Professor of Medicine and Associate Director, Cutaneous Oncology Program at the University of Colorado Denver, Division of Medical Oncology. He is a diplomat in medical oncology.
Dr. Lewis is a member of the American Society of Clinical Oncology, the Southwest Oncology Group and the Society for Melanoma Research. Author of over 50 publications, Dr. Lewis has also presented more than 50 lectures and more than 35 abstracts. He is also an ad hoc reviewer for the journals Cancer, Cancer Investigation, Current Drug Targets, Expert Opinion on Biological Therapy, and The Oncologist.
Dr. Lewis is a member of the American Society of Clinical Oncology, the Southwest Oncology Group and the Society for Melanoma Research. Author of over 50 publications, Dr. Lewis has also presented more than 50 lectures and more than 35 abstracts. He is also an ad hoc reviewer for the journals Cancer, Cancer Investigation, Current Drug Targets, Expert Opinion on Biological Therapy, and The Oncologist.
Jean Y. Tang, MD, PhD
Jean Y. Tang, MD, PhD
Assistant Professor of Dermatology
Stanford University Medical Center
Redwood City, CA
Bio
Jean Y. Tang, MD, PhD, graduated from Stanford University School of Medicine and completed an internship at Santa Clara Valley Medical Center. From there, Dr. Tang completed a residency in dermatology at Stanford University School of Medicine, and a post-doctoral fellowship at University of California, San Francisco. Dr. Tang is currently an assistant professor at Stanford University in the Department of Dermatology.
Author of over 40 publications, Dr. Tang currently is co-investigator on two research grants funded by the National Institutes of Health, for "MIM Function in Epithelial Neoplasia" and a continuing follow-up of participants of the WHI clinical trials. She also is the principal investigator on the Damon Runyon Clinical Investigator Award, the goal of which is to determine the genetic mutations driving drug resistance in BCC tumors from patients.
Author of over 40 publications, Dr. Tang currently is co-investigator on two research grants funded by the National Institutes of Health, for "MIM Function in Epithelial Neoplasia" and a continuing follow-up of participants of the WHI clinical trials. She also is the principal investigator on the Damon Runyon Clinical Investigator Award, the goal of which is to determine the genetic mutations driving drug resistance in BCC tumors from patients.
| 1. | Use the latest evidence on the benefits and risks of current and emerging medical and surgical treatments for all stages of BCC to improve patient outcomes. | 2. | Implement current treatment guidelines for all stages of BCC. |
| 3. | Integrate into practice effective co-management strategies for treating patients with BCC. |
| 1. | Use the latest evidence on the benefits and risks of current and emerging medical and surgical treatments for all stages of BCC to improve patient outcomes. |
| 2. | Implement current treatment guidelines for all stages of BCC. |
| 3. | Integrate into practice effective co-management strategies for treating patients with BCC. |
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty Disclosures
- Ragini Kudchadkar, MD, has affiliations with Genentech, BMS (Consulting); Genentech, BMS (Speaker's Bureau).
- Karl Lewis, MD, has affiliations with Genentech (Consulting); Genentech and Novartis (Research).
- Jean Y. Tang, MD, PhD, has affiliations with Genentech, BCC Registry (Consulting).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
RMEI, LLC
- Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
- Cindy Kunzer has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Estimated time to complete: 1 hour
Medium: Internet
Estimated time to complete: 1 hour
Medium: Internet
FEE INFORMATION
There is no fee for this educational activity.
COMMERCIAL SUPPORT
This activity is jointly sponsored by RMEI, LLC and Postgraduate Institute for Medicine. RMEI gratefully acknowledges an educational grant from Genentech in support of this CME activity.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 65% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
